CORRECTING and REPLACING Kos Announces Presentation at the Bank of America 2006 Healthcare Conference
05 Mai 2006 - 4:51PM
Business Wire
First graph, second sentence of release should read: Kos'
presentation will take place at 10:00 am PT on Tuesday, May 16,
2006 (sted Kos' presentation will take place at 10:00 am ET on
Tuesday, May 16, 2006.). The corrected release reads: KOS ANNOUNCES
PRESENTATION AT THE BANK OF AMERICA 2006 HEALTHCARE CONFERENCE Kos
Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that Adrian
Adams, President and Chief Executive Officer, will present at the
Bank of America 2006 Healthcare Conference, which is being held May
16 - May 18, 2006 in Las Vegas, Nevada. Kos' presentation will take
place at 10:00 am PT on Tuesday, May 16, 2006. Interested parties
can access the webcast information by going to the investor
relations section of Kos' website at www.kospharm.com, and
referencing upcoming events. About Kos Kos Pharmaceuticals, Inc. is
a fully integrated specialty pharmaceutical company engaged in
developing, commercializing, manufacturing and marketing
proprietary prescription products for the treatment of chronic
diseases with a particular focus on the cardiovascular, metabolic
and respiratory disease areas. The Company's principal product
development strategy is to reformulate existing pharmaceutical
products with large market potential to improve safety, efficacy,
and patient compliance. Kos' strategy also includes making measured
investments in new chemical entity research through in-house and
sponsored research, scientific in-licensing and general corporate
development activities. The Company currently markets Niaspan(R)
and Advicor(R) for the treatment of cholesterol disorders,
Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the
treatment of hypertension and angina, and Teveten(R) and
Teveten(R)HCT for the treatment of hypertension. Kos has a strong
and growing research and development pipeline including proprietary
drug delivery technologies in solid-dose, inhalation and aerosol
metered-dose device administration to help fuel sustained, organic
sales growth into the future. Certain statements in this press
release, including statements relating to the Company's strong and
growing research and development pipeline and future sales growth
are forward-looking and are subject to risks and uncertainties
which may cause actual results to differ materially from those
projected in a forward-looking statement. These risks and
uncertainties include the Company's ability to successfully develop
and commercialize new products under development, the Company's
ability to enter into new business development and corporate
opportunities, the progress of the company's research and
development pipeline, the protection afforded by the Company's
patents, the effect of conditions in the pharmaceutical industry
and the economy in general, and the Company's ability to maintain
compliance with FDA. A more detailed discussion of risks attendant
to the forward-looking statements included in this press release
are set forth in the "Forward-Looking information: Certain
Cautionary Statements" section of the Company's Annual Report on
Form 10-K for the year ended December 31, 2005, filed with the
Securities and Exchange Commission, and in other reports filed with
the SEC.
Kos (NASDAQ:KOSP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Kos (NASDAQ:KOSP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Kos Pharmaceuticals (NASDAQ): 0 Nachrichtenartikel
Weitere Kos Pharmaceuticals, Inc. News-Artikel